Elobopa (Eltrombopag) 

Elobopa (Eltrombopag) contains eltrombopag, which belongs to a group of medicines called thrombopoietin receptor agonists. It is used to help increase the number of platelets in your blood. Platelets are blood cells that help to reduce or prevent bleeding.

Elobopa (Eltrombopag) is used to treat a bleeding disorder called immune (idiopathic) thrombocytopenic purpura (ITP) in patients aged 1 year and above who have already taken other medicines (corticosteroids or immunoglobulins), which have not worked.

 ITP is caused by a low blood platelet count (thrombocytopenia). People with ITP have an increased risk of bleeding. Symptoms patients with ITP may notice include petechiae (pinpoint-sized flat round red spots under the skin), bruising, nosebleeds, bleeding gums and not being able to control bleeding if they are cut or injured.

Elobopa (Eltrombopag) can also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment. Many people with hepatitis C have low platelet counts, not only as a result of the disease, but also due to some of the antiviral medicines that are used to treat it. Taking Elobopa (Eltrombopag) may make it easier for you to complete a full course of antiviral medicine (peginterferon and ribavirin).

Elobopa (Eltrombopag) may also be used to treat adult patients with low blood counts caused by severe aplastic anaemia (SAA).